Massachusetts Financial Services Co. MA Trims Position in Health Catalyst, Inc. (NASDAQ:HCAT)

Massachusetts Financial Services Co. MA decreased its position in shares of Health Catalyst, Inc. (NASDAQ:HCAT) by 2.4% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 324,002 shares of the company’s stock after selling 7,845 shares during the quarter. Massachusetts Financial Services Co. MA’s holdings in Health Catalyst were worth $2,637,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Principal Financial Group Inc. increased its position in Health Catalyst by 6.9% during the second quarter. Principal Financial Group Inc. now owns 29,469 shares of the company’s stock worth $188,000 after purchasing an additional 1,907 shares during the last quarter. Harbor Capital Advisors Inc. increased its position in Health Catalyst by 21.3% during the third quarter. Harbor Capital Advisors Inc. now owns 11,764 shares of the company’s stock worth $96,000 after purchasing an additional 2,064 shares during the last quarter. The Manufacturers Life Insurance Company increased its position in Health Catalyst by 10.3% during the second quarter. The Manufacturers Life Insurance Company now owns 23,162 shares of the company’s stock worth $148,000 after purchasing an additional 2,164 shares during the last quarter. Creative Planning increased its position in Health Catalyst by 13.2% during the third quarter. Creative Planning now owns 21,348 shares of the company’s stock worth $174,000 after purchasing an additional 2,486 shares during the last quarter. Finally, Quarry LP increased its position in Health Catalyst by 59.4% during the second quarter. Quarry LP now owns 7,002 shares of the company’s stock worth $45,000 after purchasing an additional 2,610 shares during the last quarter. Hedge funds and other institutional investors own 85.00% of the company’s stock.

Insider Buying and Selling at Health Catalyst

In other Health Catalyst news, COO Daniel Lesueur sold 5,209 shares of the stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $7.70, for a total transaction of $40,109.30. Following the transaction, the chief operating officer now directly owns 129,690 shares in the company, valued at $998,613. This represents a 3.86 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Kevin Lee Freeman sold 7,500 shares of the stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $7.22, for a total transaction of $54,150.00. Following the transaction, the insider now owns 255,881 shares in the company, valued at $1,847,460.82. This trade represents a 2.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 34,068 shares of company stock worth $257,555 in the last ninety days. 2.50% of the stock is owned by insiders.

Health Catalyst Price Performance

HCAT opened at $8.50 on Wednesday. The company has a fifty day simple moving average of $8.13 and a 200 day simple moving average of $7.29. The firm has a market cap of $517.23 million, a price-to-earnings ratio of -6.30 and a beta of 1.32. Health Catalyst, Inc. has a twelve month low of $5.42 and a twelve month high of $11.41. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.32.

Health Catalyst (NASDAQ:HCAT) last released its quarterly earnings results on Wednesday, November 6th. The company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). The firm had revenue of $76.40 million for the quarter, compared to analyst estimates of $76.27 million. Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. Health Catalyst’s revenue for the quarter was up 3.5% on a year-over-year basis. During the same period in the previous year, the business posted ($0.22) earnings per share. Equities research analysts expect that Health Catalyst, Inc. will post -0.35 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on HCAT shares. JPMorgan Chase & Co. upped their price target on shares of Health Catalyst from $10.00 to $13.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 4th. Evercore ISI upped their price target on shares of Health Catalyst from $8.00 to $10.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 8th. Citigroup increased their price objective on shares of Health Catalyst from $9.00 to $10.50 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Cantor Fitzgerald reissued an “overweight” rating and issued a $16.00 price objective on shares of Health Catalyst in a research report on Friday, October 4th. Finally, Piper Sandler reissued an “overweight” rating and issued a $12.00 price objective (up previously from $11.00) on shares of Health Catalyst in a research report on Tuesday. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, Health Catalyst has a consensus rating of “Moderate Buy” and a consensus price target of $11.79.

Health Catalyst Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.